neglected disease research and development how much are we really spending被忽视疾病的研究和发展我们真的花费了多少.pdfVIP

Policy Forum Neglected Disease Research and Development: How Much Are We Really Spending? Mary Moran*, Javier Guzman, Anne-Laure Ropars, Alina McDonald, Nicole Jameson, Brenda Omune, Sam Ryan, Lindsey Wu he need for new pharmaceutical first G-FINDER report (http://www. developing-country presentations of tools to prevent and treat /prpppubs). Type II diseases, which are “incident in Tneglected diseases is widely both rich and poor countries, but with accepted [1]. The creation of a Methodology a substantial proportion of the cases in vaccine for HIV/AIDS, more effective The chief principle of the G-FINDER the poor countries” and where RD diagnostics for tuberculosis (TB), and survey was to provide consistent, is “not in proportion to global need better treatments for leishmaniasis comparable, comprehensive data on or addressed to the specific disease and sleeping sickness would greatly neglected disease RD investments to conditions of poor countries” [8]. Type improve health in the developing those working in the field. I diseases, which occur commonly in world in line with the United Nations Survey design therefore focused on both rich and poor countries, were Millennium Development Goals. two elements. The first was disease, excluded on the grounds that “the However, funders wishing to invest in product, and research scope; the incentives for RD exist